Neurogene Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - NGNE
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Neurogene Inc. (NASDAQ:NGNE) for potential violations of federal securities laws. This follows a press release by Neurogene reporting interim clinical data from a Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome.
November 15, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neurogene Inc. is under investigation by Levi & Korsinsky for potential securities law violations following the release of interim clinical data from a Phase 1/2 trial.
The investigation by Levi & Korsinsky into potential securities law violations could negatively impact investor confidence in Neurogene Inc. This follows the release of clinical trial data, which may have prompted the investigation. Legal issues often lead to stock price volatility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100